1. Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor.
- Author
-
Kinne, Nolan MD, Hodeib, Melissa DO, Kashani, Nader A. MD, Tewari, Devansu MD, MBA, Kinne, Nolan, Hodeib, Melissa, Kashani, Nader A, and Tewari, Devansu
- Subjects
- *
ANAPLASTIC lymphoma kinase , *SARCOMA , *MEDICAL personnel , *KINASE inhibitors , *FLUORESCENCE in situ hybridization , *ANAPLASTIC thyroid cancer - Abstract
Tumor testing identified anaplastic lymphoma kinase gene rearrangements, and the patient was placed on crizotinib 250 mg orally twice daily for 20 weeks. Nagumo et al and Butrynski et al have reported cases that show drastic improvement in tumor size with use of crizotinib in patients with anaplastic lymphoma kinase rearrangement.2,3 Studies such as these have led the National Comprehensive Cancer Network to include crizotinib as standard treatment for patients with inflammatory myofibroblastic sarcomas and anaplastic lymphoma kinase rearrangements.4 Given the longevity of our patient and the success of others, we strongly encourage health care providers to perform fluorescence in situ hybridization testing of rare inflammatory myofibroblastic sarcomas to assess for anaplastic lymphoma kinase rearrangements. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF